GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Komipharm International Co Ltd (XKRX:041960) » Definitions » Gross Profit

Komipharm International Co (XKRX:041960) Gross Profit : ₩19,436 Mil (TTM As of Sep. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Komipharm International Co Gross Profit?

Komipharm International Co's gross profit for the three months ended in Sep. 2024 was ₩3,853 Mil. Komipharm International Co's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was ₩19,436 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Komipharm International Co's gross profit for the three months ended in Sep. 2024 was ₩3,853 Mil. Komipharm International Co's Revenue for the three months ended in Sep. 2024 was ₩10,990 Mil. Therefore, Komipharm International Co's Gross Margin % for the quarter that ended in Sep. 2024 was 35.06%.

Komipharm International Co had a gross margin of 35.06% for the quarter that ended in Sep. 2024 => Competition eroding margins

During the past 13 years, the highest Gross Margin % of Komipharm International Co was 36.00%. The lowest was 27.94%. And the median was 30.82%.


Komipharm International Co Gross Profit Historical Data

The historical data trend for Komipharm International Co's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Komipharm International Co Gross Profit Chart

Komipharm International Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11,416.99 13,376.23 11,234.25 11,458.83 12,658.17

Komipharm International Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,212.70 2,014.92 5,016.83 8,551.38 3,852.87

Competitive Comparison of Komipharm International Co's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Komipharm International Co's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Komipharm International Co's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Komipharm International Co's Gross Profit distribution charts can be found below:

* The bar in red indicates where Komipharm International Co's Gross Profit falls into.



Komipharm International Co Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Komipharm International Co's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=42647.035 - 29988.868
=12,658

Komipharm International Co's Gross Profit for the quarter that ended in Sep. 2024 is calculated as

Gross Profit (Q: Sep. 2024 )=Revenue - Cost of Goods Sold
=10989.727 - 7136.861
=3,853

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩19,436 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Komipharm International Co's Gross Margin % for the quarter that ended in Sep. 2024 is calculated as

Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=3,853 / 10989.727
=35.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Komipharm International Co  (XKRX:041960) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Komipharm International Co had a gross margin of 35.06% for the quarter that ended in Sep. 2024 => Competition eroding margins


Komipharm International Co Gross Profit Related Terms

Thank you for viewing the detailed overview of Komipharm International Co's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Komipharm International Co Business Description

Traded in Other Exchanges
N/A
Address
1236-6 Jungwang-Dong, Sihung, Gyeonggi, KOR, 429-450
Komipharm International Co Ltd is involved in the healthcare sector based in Korea. Its core business includes development and manufacture of veterinary vaccines and veterinary pharmaceuticals. The company produces its products under two divisions: veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle. The other division is made up of veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis and swine erysipelas.

Komipharm International Co Headlines

No Headlines